{"id":68192,"date":"2026-06-15T20:48:43","date_gmt":"2026-06-15T12:48:43","guid":{"rendered":"https:\/\/flcube.com\/?p=68192"},"modified":"2026-06-15T20:48:48","modified_gmt":"2026-06-15T12:48:48","slug":"micot-pharmaceutical-successfully-lists-on-hong-kong-stock-exchange-with-hk1-22-billion-ipo","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68192","title":{"rendered":"Micot Pharmaceutical Successfully Lists on Hong Kong Stock Exchange with HK$1.22 Billion IPO"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shaanxi Micot Pharmaceutical Technology Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/2355:HKG\">HKG: 2355<\/a>)<\/strong> announced its successful listing on the <strong>Hong Kong Stock Exchange<\/strong> through an <strong>initial public offering (IPO)<\/strong>, raising approximately <strong>HK$1.22 billion<\/strong> (US$156 million) with a global offering of <strong>58,054,400 H shares<\/strong> at <strong>HKD21.0 per share<\/strong>. The company focuses on the discovery, development, and commercialization of <strong>bi-\/multi-specific peptide drugs<\/strong> for <strong>metabolic diseases<\/strong> and <strong>cardiovascular and cerebrovascular disorders<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-ipo-details\" class=\"wp-block-heading\">IPO Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Exchange<\/strong><\/td><td>Hong Kong Stock Exchange (HKG)<\/td><\/tr><tr><td><strong>Ticker Symbol<\/strong><\/td><td>2355<\/td><\/tr><tr><td><strong>Shares Offered<\/strong><\/td><td>58,054,400 H shares<\/td><\/tr><tr><td><strong>Offering Price<\/strong><\/td><td>HKD21.0 per share<\/td><\/tr><tr><td><strong>Gross Proceeds<\/strong><\/td><td>HK$1.22 billion (approximately US$156 million)<\/td><\/tr><tr><td><strong>Listing Date<\/strong><\/td><td>June 15, 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-company-profile-amp-pipeline\" class=\"wp-block-heading\">Company Profile &amp; Pipeline<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Focus Area:<\/strong> Bi-\/multi-specific peptide therapeutics<\/li>\n\n\n\n<li><strong>Therapeutic Indications:<\/strong> Metabolic diseases, cardiovascular disorders, cerebrovascular disorders<\/li>\n\n\n\n<li><strong>Pipeline Composition:<\/strong> One core product + six additional drug candidates<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Core product in Phase III clinical development<\/li>\n\n\n\n<li><strong>Technology Platform:<\/strong> Proprietary peptide engineering and multi-receptor targeting capabilities<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-core-product-mt1013\" class=\"wp-block-heading\">Core Product \u2013 MT1013<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Molecule Type<\/strong><\/td><td>Dual-receptor agonist peptide<\/td><\/tr><tr><td><strong>Targets<\/strong><\/td><td>Calcium-sensing receptor (CaSR) and Osteoglycin (OGP) receptors<\/td><\/tr><tr><td><strong>Primary Indication<\/strong><\/td><td>Secondary hyperparathyroidism in chronic kidney disease (CKD-SHPT)<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Phase III<\/td><\/tr><tr><td><strong>Additional Indications<\/strong><\/td><td>CKD-mineral and bone disorder (CKD-MBD) with osteoporosis, non-dialysis CKD-SHPT<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-opportunity-analysis\" class=\"wp-block-heading\">Market Opportunity Analysis<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CKD-SHPT Market:<\/strong> Significant unmet medical need with limited treatment options for secondary hyperparathyroidism in CKD patients<\/li>\n\n\n\n<li><strong>Peptide Therapeutics:<\/strong> Growing interest in peptide-based approaches due to high specificity and favorable safety profiles<\/li>\n\n\n\n<li><strong>Dual-Receptor Strategy:<\/strong> Novel mechanism addressing both calcium regulation (CaSR) and bone metabolism (OGP) simultaneously<\/li>\n\n\n\n<li><strong>Geographic Focus:<\/strong> Initial focus on China market with potential for global expansion<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-use-of-ipo-proceeds\" class=\"wp-block-heading\">Strategic Use of IPO Proceeds<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Development:<\/strong> Advance MT1013 through Phase III completion and regulatory submissions<\/li>\n\n\n\n<li><strong>Pipeline Expansion:<\/strong> Fund development of six additional drug candidates across metabolic and cardiovascular indications<\/li>\n\n\n\n<li><strong>Manufacturing Capacity:<\/strong> Invest in GMP-compliant peptide manufacturing facilities<\/li>\n\n\n\n<li><strong>Commercial Infrastructure:<\/strong> Build sales and marketing capabilities for product launch readiness<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape\" class=\"wp-block-heading\">Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CKD-SHPT Therapies:<\/strong> Current market dominated by calcimimetics and vitamin D analogs with limitations in efficacy and side effects<\/li>\n\n\n\n<li><strong>Innovation Gap:<\/strong> Limited dual-targeting approaches in the CKD-MBD space<\/li>\n\n\n\n<li><strong>Peptide Advantage:<\/strong> MT1013&#8217;s dual-receptor mechanism offers potential for improved efficacy over single-target agents<\/li>\n\n\n\n<li><strong>Market Position:<\/strong> Among the most advanced Chinese biotech companies focused specifically on peptide therapeutics<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-financial-outlook-amp-milestones\" class=\"wp-block-heading\">Financial Outlook &amp; Milestones<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Timeline:<\/strong> Potential NDA submission for MT1013 in 2027 pending Phase III results<\/li>\n\n\n\n<li><strong>Revenue Projections:<\/strong> Anticipated commercial launch in 2028 assuming successful regulatory approval<\/li>\n\n\n\n<li><strong>Pipeline Progression:<\/strong> Additional candidates expected to enter clinical trials within 12-24 months<\/li>\n\n\n\n<li><strong>Global Strategy:<\/strong> Potential partnerships for international development and commercialization<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and commercial expectations. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and market competition.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061500010_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026061500010_c.\"><\/object><a id=\"wp-block-file--media-5aa56dce-fdf4-4605-afcf-708a1190a535\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061500010_c.pdf\">2026061500010_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061500010_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-5aa56dce-fdf4-4605-afcf-708a1190a535\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2355) announced its successful listing on the Hong&#8230;<\/p>\n","protected":false},"author":1,"featured_media":68193,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4797,72,4205],"class_list":["post-68192","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-hkg-2355","tag-ipo","tag-micot"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Micot Pharmaceutical Successfully Lists on Hong Kong Stock Exchange with HK$1.22 Billion IPO - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2355) announced its successful listing on the Hong Kong Stock Exchange through an initial public offering (IPO), raising approximately HK$1.22 billion (US$156 million) with a global offering of 58,054,400 H shares at HKD21.0 per share. The company focuses on the discovery, development, and commercialization of bi-\/multi-specific peptide drugs for metabolic diseases and cardiovascular and cerebrovascular disorders.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68192\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Micot Pharmaceutical Successfully Lists on Hong Kong Stock Exchange with HK$1.22 Billion IPO\" \/>\n<meta property=\"og:description\" content=\"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2355) announced its successful listing on the Hong Kong Stock Exchange through an initial public offering (IPO), raising approximately HK$1.22 billion (US$156 million) with a global offering of 58,054,400 H shares at HKD21.0 per share. The company focuses on the discovery, development, and commercialization of bi-\/multi-specific peptide drugs for metabolic diseases and cardiovascular and cerebrovascular disorders.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68192\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T12:48:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-15T12:48:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1503.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68192#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68192\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Micot Pharmaceutical Successfully Lists on Hong Kong Stock Exchange with HK$1.22 Billion IPO\",\"datePublished\":\"2026-06-15T12:48:43+00:00\",\"dateModified\":\"2026-06-15T12:48:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68192\"},\"wordCount\":445,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68192#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1503.webp\",\"keywords\":[\"HKG: 2355\",\"IPO\",\"Micot Pharmaceutical Technology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68192#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68192\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68192\",\"name\":\"Micot Pharmaceutical Successfully Lists on Hong Kong Stock Exchange with HK$1.22 Billion IPO - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68192#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68192#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1503.webp\",\"datePublished\":\"2026-06-15T12:48:43+00:00\",\"dateModified\":\"2026-06-15T12:48:48+00:00\",\"description\":\"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2355) announced its successful listing on the Hong Kong Stock Exchange through an initial public offering (IPO), raising approximately HK$1.22 billion (US$156 million) with a global offering of 58,054,400 H shares at HKD21.0 per share. The company focuses on the discovery, development, and commercialization of bi-\\\/multi-specific peptide drugs for metabolic diseases and cardiovascular and cerebrovascular disorders.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68192#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68192\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68192#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1503.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1503.webp\",\"width\":1080,\"height\":608,\"caption\":\"Micot Pharmaceutical Successfully Lists on Hong Kong Stock Exchange with HK$1.22 Billion IPO\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68192#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Micot Pharmaceutical Successfully Lists on Hong Kong Stock Exchange with HK$1.22 Billion IPO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Micot Pharmaceutical Successfully Lists on Hong Kong Stock Exchange with HK$1.22 Billion IPO - Insight, China&#039;s Pharmaceutical Industry","description":"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2355) announced its successful listing on the Hong Kong Stock Exchange through an initial public offering (IPO), raising approximately HK$1.22 billion (US$156 million) with a global offering of 58,054,400 H shares at HKD21.0 per share. The company focuses on the discovery, development, and commercialization of bi-\/multi-specific peptide drugs for metabolic diseases and cardiovascular and cerebrovascular disorders.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68192","og_locale":"en_US","og_type":"article","og_title":"Micot Pharmaceutical Successfully Lists on Hong Kong Stock Exchange with HK$1.22 Billion IPO","og_description":"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2355) announced its successful listing on the Hong Kong Stock Exchange through an initial public offering (IPO), raising approximately HK$1.22 billion (US$156 million) with a global offering of 58,054,400 H shares at HKD21.0 per share. The company focuses on the discovery, development, and commercialization of bi-\/multi-specific peptide drugs for metabolic diseases and cardiovascular and cerebrovascular disorders.","og_url":"https:\/\/flcube.com\/?p=68192","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-15T12:48:43+00:00","article_modified_time":"2026-06-15T12:48:48+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1503.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68192#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68192"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Micot Pharmaceutical Successfully Lists on Hong Kong Stock Exchange with HK$1.22 Billion IPO","datePublished":"2026-06-15T12:48:43+00:00","dateModified":"2026-06-15T12:48:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68192"},"wordCount":445,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=68192#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1503.webp","keywords":["HKG: 2355","IPO","Micot Pharmaceutical Technology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68192#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68192","url":"https:\/\/flcube.com\/?p=68192","name":"Micot Pharmaceutical Successfully Lists on Hong Kong Stock Exchange with HK$1.22 Billion IPO - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=68192#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=68192#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1503.webp","datePublished":"2026-06-15T12:48:43+00:00","dateModified":"2026-06-15T12:48:48+00:00","description":"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2355) announced its successful listing on the Hong Kong Stock Exchange through an initial public offering (IPO), raising approximately HK$1.22 billion (US$156 million) with a global offering of 58,054,400 H shares at HKD21.0 per share. The company focuses on the discovery, development, and commercialization of bi-\/multi-specific peptide drugs for metabolic diseases and cardiovascular and cerebrovascular disorders.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68192#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68192"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=68192#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1503.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1503.webp","width":1080,"height":608,"caption":"Micot Pharmaceutical Successfully Lists on Hong Kong Stock Exchange with HK$1.22 Billion IPO"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68192#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Micot Pharmaceutical Successfully Lists on Hong Kong Stock Exchange with HK$1.22 Billion IPO"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1503.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68192","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68192"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68192\/revisions"}],"predecessor-version":[{"id":68195,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68192\/revisions\/68195"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/68193"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68192"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68192"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68192"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}